Sort   by:  
 Page size 
UnknownIntermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.
Not available
S-EPMC3929885 | biostudies-literature
UnknownPhase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.
Not available
S-EPMC7356710 | biostudies-literature
UnknownActivity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
Not available
S-EPMC5740387 | biostudies-literature
UnknownActivity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.
Not available
S-EPMC5786802 | biostudies-literature
UnknownAxitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study.
Not available
S-EPMC4467642 | biostudies-literature
UnknownPatient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
Not available
S-EPMC3668468 | biostudies-literature
UnknownEffect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
Not available
S-EPMC5568082 | biostudies-literature
UnknownHuman primed and naive PSCs are both able to differentiate into trophoblast stem cells.
Not available
S-EPMC9669397 | biostudies-literature
UnknownMAP17 Is a Necessary Activator of Renal Na+/Glucose Cotransporter SGLT2.
Not available
S-EPMC5198278 | biostudies-literature
UnknownEnzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK.
Not available
S-EPMC12909104 | biostudies-literature
Sort   by:  
 Page size